Terms: = Prostate cancer AND ERG, P11308, 2078 AND Treatment
244 results:
1. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract] [Full Text] [Related]
2. Identification of recurrent BRAF non-V600 mutations in intraductal carcinoma of the prostate in Chinese populations.
Hu J; Chen X; Sun F; Liu L; Liu L; Yang Z; Zhang H; Yu Z; Zhao R; Wang Y; Liu H; Yang X; Sun F; Han B
Neoplasia; 2024 Apr; 50():100983. PubMed ID: 38417222
[TBL] [Abstract] [Full Text] [Related]
3. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
4. Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility.
O'Malley DE; Raspin K; Melton PE; Burdon KP; Dickinson JL; FitzGerald LM
Br J Cancer; 2024 Feb; 130(3):347-357. PubMed ID: 37945750
[TBL] [Abstract] [Full Text] [Related]
5. Club-like cells in proliferative inflammatory atrophy of the prostate.
Huang FW; Song H; Weinstein HN; Xie J; Cooperberg MR; Hicks J; Mummert L; De Marzo AM; Sfanos KS
J Pathol; 2023 Sep; 261(1):85-95. PubMed ID: 37550827
[TBL] [Abstract] [Full Text] [Related]
6. Investigation of Clinically Significant Molecular Aberrations in Patients with prostate cancer: Implications for Personalized treatment, Prognosis and Genetic Testing.
Fountzilas E; Kouspou M; Eliades A; Papadopoulou K; Bournakis E; Goussia A; Tsiatas M; Achilleos A; Tsangaras K; Billioud G; Loizides C; Lemesios C; Kypri E; Ioannides M; Koumbaris G; Levva S; Vakalopoulos I; Paliouras A; Pervana S; Koinis F; Bumci R; Christopoulou A; Meditskou S; Psyrri A; Boukovinas I; Visvikis A; Karavasilis V; Koukoulis GK; Kotsakis A; Giannakis D; Fountzilas G; Patsalis PC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511593
[TBL] [Abstract] [Full Text] [Related]
7. The potential role of the microbiota in prostate cancer pathogenesis and treatment.
Pernigoni N; Guo C; Gallagher L; Yuan W; Colucci M; Troiani M; Liu L; Maraccani L; Guccini I; Migliorini D; de Bono J; Alimonti A
Nat Rev Urol; 2023 Dec; 20(12):706-718. PubMed ID: 37491512
[TBL] [Abstract] [Full Text] [Related]
8. Transcriptome Profiling of prostate cancer, Considering Risk Groups and the TMPRSS2-erg Molecular Subtype.
Kobelyatskaya AA; Pudova EA; Katunina IV; Snezhkina AV; Fedorova MS; Pavlov VS; Kotelnikova AO; Nyushko KM; Alekseev BY; Krasnov GS; Kudryavtseva AV
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298233
[TBL] [Abstract] [Full Text] [Related]
9. Development and characterization of an ETV1 rabbit monoclonal antibody for the immunohistochemical detection of ETV1 expression in cancer tissue specimens.
Schafer C; Young D; Singh H; Jayakrishnan R; Banerjee S; Song Y; Dobi A; Petrovics G; Srivastava S; Srivastava S; Sesterhenn IA; Chesnut GT; Tan SH
J Immunol Methods; 2023 Jul; 518():113493. PubMed ID: 37196930
[TBL] [Abstract] [Full Text] [Related]
10. Clinical Characteristics and Survival Analysis of Patients With Second Primary Malignancies After Hepatocellular Carcinoma Liver Transplantation: A SEER-based Analysis.
Ding Q; Wang K; Li Y; Peng P; Zhang D; Chang D; Wang W; Ren L; Tang F; Li Z
Am J Clin Oncol; 2023 Jul; 46(7):284-292. PubMed ID: 37145881
[TBL] [Abstract] [Full Text] [Related]
11. The performance and limitations of PCA3, TMPRSS2:erg, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics.
Mytsyk Y; Nakonechnyi Y; Dosenko V; Kowal P; Pietrus M; Gazdikova K; Labudova M; Caprnda M; Prosecky R; Dragasek J; Kruzliak P; Dats R
Clin Biochem; 2023 Jun; 116():120-127. PubMed ID: 37121562
[TBL] [Abstract] [Full Text] [Related]
12. Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:erg Fusion-Positive prostate cancer.
Li C; Zhang J; Wu Q; Kumar A; Pan G; Kelvin DJ
Mol Cancer Ther; 2023 Mar; 22(3):306-316. PubMed ID: 36622760
[TBL] [Abstract] [Full Text] [Related]
13. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
Fernandez-Perez MP; Perez-Navarro E; Alonso-Gordoa T; Conteduca V; Font A; Vázquez-Estévez S; González-Del-Alba A; Wetterskog D; Antonarakis ES; Mellado B; Fernandez-Calvo O; Méndez-Vidal MJ; Climent MA; Duran I; Gallardo E; Rodriguez Sanchez A; Santander C; Sáez MI; Puente J; Tudela J; Martínez A; López-Andreo MJ; Padilla J; Lozano R; Hervas D; Luo J; de Giorgi U; Castellano D; Attard G; Grande E; Gonzalez-Billalabeitia E
Prostate; 2023 Mar; 83(4):376-384. PubMed ID: 36564933
[TBL] [Abstract] [Full Text] [Related]
14. Emerging Developments in ETS-Positive prostate cancer Therapy.
Bowling GC; Rands MG; Dobi A; Eldhose B
Mol Cancer Ther; 2023 Feb; 22(2):168-178. PubMed ID: 36511830
[TBL] [Abstract] [Full Text] [Related]
15. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical prostatectomy for High-risk prostate cancer.
Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
[TBL] [Abstract] [Full Text] [Related]
16. Differences in prostate cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different?
Zhou CD; Pettersson A; Plym A; Tyekucheva S; Penney KL; Sesso HD; Kantoff PW; Mucci LA; Stopsack KH
Cancer Prev Res (Phila); 2022 Dec; 15(12):815-825. PubMed ID: 36125434
[TBL] [Abstract] [Full Text] [Related]
17. [Epidemiological and clinicopathological characteristics of prostate cancer in Hunan].
Zou B; Long Y; Yang ZM; Gao RS; Lin QF; Dai XJ; Yi G; Wang QZ; Zhou Q; Zhang XB
Zhonghua Nan Ke Xue; 2022 Sep; 28(9):786-791. PubMed ID: 37839003
[TBL] [Abstract] [Full Text] [Related]
18. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract] [Full Text] [Related]
19. In situ expression of erg protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis.
Kidd SG; Bogaard M; Carm KT; Bakken AC; Maltau AMV; Løvf M; Lothe RA; Axcrona K; Axcrona U; Skotheim RI
Mol Oncol; 2022 Aug; 16(15):2810-2822. PubMed ID: 35574900
[TBL] [Abstract] [Full Text] [Related]
20. Targeting cyclin-dependent kinase 7-association between CDK7 and pMED1 expression in prostate cancer tissue.
Paulsen FO; Kang D; Becker F; Roth D; Joerg V; Dreyer E; Roesch MC; Seidel C; Merseburger AS; Kirfel J; Sailer V; Offermann A; Perner S
Carcinogenesis; 2022 Sep; 43(8):779-786. PubMed ID: 35512686
[TBL] [Abstract] [Full Text] [Related]
[Next]
